The aging eye experiences physiological changes that include decreased visual function and increased risk of retinal degeneration. Although there are transcriptomic signatures in the aging retina that correlate with these physiological changes, the gene regulatory mechanisms that contribute to cellular homeostasis during aging remain to be determined. Here, we integrated ATAC-seq and RNA-seq data to identify 57 transcription factors that showed differential activity in aging Drosophila photoreceptors. These 57 age-regulated transcription factors include two circadian regulators, Clock and Cycle, that showed sustained increased activity during aging. When we disrupted the Clock:Cycle complex by expressing a dominant negative version of Clock (ClkDN) in adult photoreceptors, we observed changes in expression of 15–20% of genes including key components of the phototransduction machinery and many eye-specific transcription factors. Using ATAC-seq, we showed that expression of ClkDN in photoreceptors leads to changes in activity of 37 transcription factors and causes a progressive decrease in global levels of chromatin accessibility in photoreceptors. Supporting a key role for Clock-dependent transcription in the eye, expression of ClkDN in photoreceptors also induced light-dependent retinal degeneration and increased oxidative stress, independent of light exposure. Together, our data suggests that the circadian regulators Clock and Cycle act as neuroprotective factors in the aging eye by directing gene regulatory networks that maintain expression of the phototransduction machinery and counteract oxidative stress.
3 October 2022 in Journal of Mammary Gland Biology and Neoplasia
Epithelial-mesenchymal plasticity (EMP) is activated in carcinoma cells to drive metastasis and chemoresistance. Recently, we demonstrated that EMP activation results in an immunosuppressive tumor microenvironment and immunotherapy resistance in a syngeneic orthotopic murine model. However, it has yet to be shown whether this is conserved in canine carcinomas. Here, we show that in spontaneous canine mammary carcinomas (CMCs), which share clinical and molecular features with human breast cancers, EMP is linked to the recruitment of immunosuppressive cells. Additionally, we identify that the glycoprotein CD109 is associated with EMP-mediated immunosuppression in canine, murine, and human models. CD109 has been associated with tumorigenicity, but not immunosuppression in cancers of any species. Finally, we identified shared upregulation of immunosuppressive factors across multiple canine carcinomas, including oral squamous cell carcinoma, urothelial carcinoma, and pulmonary carcinoma. These findings demonstrate that EMP is associated with immunosuppression in canine carcinomas, with translational implications for human breast cancers.
Although immune checkpoint blockade (ICB) therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial–mesenchymal plasticity (EMP) leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 ICB therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in qM breast tumors sensitizes them to anti-CTLA4 ICB therapy in a CD4+ T cell–dependent manner. Moreover, EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers. Given the ability of qM cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4+ T cells as a predictive criterion for immunotherapy responsiveness. Significance: EMP enables metastasis and drives resistance to multiple treatment regimens. Our work underscores the possibility of utilizing CD4+ T cells, CD73, and cancer plasticity as predictive criteria for responsiveness to immunotherapy.
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer-a consequence of high proliferation rates, stemness, epithelial-mesenchymal plasticity, and immune evasion. Feline mammary carcinomas (FMCs) are spontaneous mammary gland cancers associated with high rates of metastasis and death. The aggressive biological behavior of FMCs, as well as their lack of expression of hormone receptors, make FMCs an excellent naturally-occurring model of human triple-negative breast cancer (TNBC). Therefore, we investigated whether FMCs of increasing histologic grade (I-III) harbor characteristics comparable to human TNBC. We performed immunohistochemistry using markers of proliferation (Ki67), stemness (Sox2), and epithelial-mesenchymal plasticity (E-cadherin, vimentin). We found that FMCs expressed high levels of Sox2 and vimentin together with a grade-associated increase in Ki67 expression. Apart from these cancer cell-intrinsic properties, knowledge on the tumor microenvironment of FMCs is limited. To this end, we assessed the presence of T-cells (CD3), total macrophages (Iba1), and immunosuppressive M2-like macrophages (CD204) in FMCs. High-grade FMCs showed increased M2-like macrophage infiltration. Moreover, samples with evidence of vascular invasion and lymph node metastasis displayed increased total and M2-like macrophage infiltration. These findings suggest that the presence of intratumoral macrophages is associated with the biological aggressiveness and metastatic potential of FMCs. Taken together, our results support FMCs as a translational model of human TNBC.
Epithelial-mesenchymal plasticity (EMP) is a cellular process activated in carcinoma cells to drive invasiveness, metastasis, and chemoresistance. Recently, we have demonstrated that activation of the EMP program also results in the assembly of an immunosuppressive tumor microenvironment and resistance to immunotherapy in an immunocompetent orthotopic murine model. However, it has yet to be shown whether these findings can be translated to canine carcinomas. Here, we show that in spontaneous canine mammary carcinomas (CMCs), which share similar histopathologic, molecular, and clinical features with human breast cancers, EMP activation is linked to the recruitment of immunosuppressive cells including regulatory T-cells and M2-like macrophages. Additionally, through transcriptomic profiling of CMCs, we identify that the glycoprotein CD109 is associated with EMP-mediated immunosuppression across canine, murine, and human breast cancer models. CD109 has been previously associated with tumorigenicity, but not immunosuppression in cancers of any species. Finally, we identified upregulation of several immunosuppressive paracrine factors across multiple canine carcinomas, including oral squamous cell carcinoma, urothelial carcinoma, and pulmonary carcinoma samples. These findings demonstrate for the first time that the EMP program is associated with immunosuppression in canine carcinomas, with direct translational implications for human breast cancers.